Alkermes plc (ALKS) |
|
26.49 0.74 (2.87%)
|
03-24 16:00 |
|
Open: |
25.73 |
Pre. Close: |
25.75 |
|
High:
|
26.53 |
Low:
|
25.51 |
|
Volume:
|
927,980 |
Market Cap:
|
4,355(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:55 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 32.04  One year: 33.48 |
| Support: |
Support1: 25.43 Support2: 21.15 |
| Resistance: |
Resistance1: 27.43 Resistance2: 28.67 |
| Pivot: |
26.57 |
| Moving Average: |
MA(5): 26.24 MA(20): 26.71
MA(100): 26.05 MA(250): 26.48 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 23.8 %D(3): 22.2 |
| RSI: |
RSI(14): 46.7 |
| 52-week: |
High: 32.79 Low: 21.75 |
| Average Vol(K): |
3-Month: 1,251 (K) 10-Days: 974 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALKS ] has closed above bottom band by 44.8%. Bollinger Bands are 31% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
26.54 - 26.7 |
26.7 - 26.86 |
|
Low:
|
25.14 - 25.32 |
25.32 - 25.5 |
|
Close:
|
26.2 - 26.48 |
26.48 - 26.75 |
|
Company Description |
|
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. |
Headline News |
Sat, 25 Mar 2023
Alkermes (NASDAQ:ALKS) Upgraded to Strong-Buy by StockNews ... - MarketBeat
Fri, 24 Mar 2023
Alkermes plc (NASDAQ:ALKS) Shares Sold by Bank of New York ... - MarketBeat
Thu, 23 Mar 2023
Journal of Clinical Psychiatry Publishes Data from Alkermes ... - PR Newswire
Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Kenneth Fisher - 3 ... - Nasdaq
Wed, 15 Mar 2023
Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why - Nasdaq
Sat, 11 Mar 2023
A Alkermes plc (NASDAQ:ALKS) insider increased their holdings by 63% last year - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
164 (M) |
| Shares Float |
148 (M) |
|
% Held by Insiders
|
1.7 (%) |
|
% Held by Institutions
|
103.1 (%) |
|
Shares Short
|
8,980 (K) |
|
Shares Short P.Month
|
9,140 (K) |
Stock Financials |
|
EPS
|
-0.94 |
|
EPS Est Next Qtl
|
-0.01 |
|
EPS Est This Year
|
-0.04 |
|
EPS Est Next Year
|
0.44 |
|
Book Value (p.s.)
|
6.34 |
|
Profit Margin (%)
|
-14.3 |
|
Operating Margin (%)
|
-12.9 |
|
Return on Assets (ttm)
|
-4.5 |
|
Return on Equity (ttm)
|
-14.7 |
|
Qtrly Rev. Growth
|
-6.1 |
|
Gross Profit (p.s.)
|
5.43 |
|
Sales Per Share
|
6.75 |
|
EBITDA (p.s.)
|
-0.4 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
21 (M) |
|
Levered Free Cash Flow
|
68 (M) |
Stock Valuations |
|
PE Ratio
|
-28.19 |
|
PEG Ratio
|
11.9 |
|
Price to Book value
|
4.17 |
|
Price to Sales
|
3.92 |
|
Price to Cash Flow
|
206.97 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
